| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 73486 |
cas:2101206-67-9，Ald-Ph-amido-PEG1-C2-Pfp ester， ADC试剂 |
70 |
kx |
2024-12-19 |
| 73487 |
Ald-Ph-amido-PEG11-NH-Boc CAS:1245813-70-0 |
92 |
zyl |
2024-12-19 |
| 73488 |
HSA-2-iminothiolane-DOTA HSA-2-亚氨基硫醇-DOTA |
88 |
h |
2024-12-19 |
| 73489 |
cas:1222787-24-7，2,5-Dioxopyrrolidin-1-yl 4-((2-((2-(2-(4-(2,6-dioxo-1,3-dipropyl-2,3,6,9-tetrahydro-1H-purin-8-yl)phenoxy)acetamido)ethyl)amino)ethyl)disulfanyl)-4-oxobutanoate |
200 |
kx |
2024-12-19 |
| 73490 |
Tr-PEG5-OH CAS:141282-24-8物理化学性质 |
91 |
zyl |
2024-12-19 |
| 73491 |
CAS: 870487-08-4，Boc-Val-Cit，(S)-2-((S)-2-((叔丁氧基羰基)氨基)-3-甲基丁酰胺基)-5-脲基戊酸 |
94 |
WYQ |
2024-12-19 |
| 73492 |
DOTA-8-Aoc-BBN[7-14]NH |
99 |
h |
2024-12-19 |
| 73493 |
Fmoc-PEG3-Val-Cit，N-Fluorenylmethoxycarbonyl-triethylene glycol-Val-Cit |
80 |
WYQ |
2024-12-19 |
| 73494 |
CAS: 2226472-28-0，DBCO-PEG4-Val-Cit-PAB-PNP |
76 |
WYQ |
2024-12-19 |
| 73495 |
CAS: 2055024-64-9，Azido-PEG4-Val-Cit-PAB-OH |
79 |
WYQ |
2024-12-19 |
| 73496 |
CAS: 870487-09-5，Boc-Val-Cit-PAB |
82 |
WYQ |
2024-12-19 |
| 73497 |
CAS:784105-33-5 Amino-PEG3-C2-acid的介绍 |
71 |
zyl |
2024-12-19 |
| 73498 |
CAS 863971-53-3：Fmoc-Val-Cit-PAB-PNP |
85 |
WYQ |
2024-12-19 |
| 73499 |
Ald-Ph-amido-PEG11-C2-NH2 CAS:1337889-01-6 |
68 |
zyl |
2024-12-19 |
| 73500 |
cas:2003260-13-5 ， MA-PEG4-Ala-Ala-PAB-PNP，ADC定制 |
70 |
wyh |
2024-12-19 |
| 73501 |
DOTA-NCS-6-Ahx-Phe 19-ST[1-19] DOTA偶联ST肽类似物 |
100 |
h |
2024-12-19 |
| 73502 |
1,4,7,10-四氮杂-n-(1-羧基-3-(4-硝基苯基)丙基)-n,N , N ‴-tris(acetic酸)环十二烷(PA-DOTA) |
66 |
h |
2024-12-19 |
| 73503 |
CAS 159858-22-7：Fmoc-Val-Cit-PAB-OH |
58 |
WYQ |
2024-12-19 |
| 73504 |
cas:5117-19-1，Octanethyl glycol ，八乙二醇的主要特点 |
94 |
zyl |
2024-12-19 |
| 73505 |
CAS 159857-79-1：Val-Cit-PAB-OH，缬氨酸（Val）、琥珀酰亚胺（Cit）和对氨基苯甲酸（PAB）的衍生物 |
99 |
WYQ |
2024-12-19 |
| 73506 |
SPDP-Val-Cit-PAB-OH，ADC定制 |
65 |
wyh |
2024-12-19 |
| 73507 |
DOTA-LVT 螯合剂DOTA偶联Lys8-血管收缩素 |
87 |
h |
2024-12-19 |
| 73508 |
cas:2054345-67-2，azido-tris(ethylenoxy)-L-alanine TFA Salt化学性质 |
82 |
zyl |
2024-12-19 |
| 73509 |
cas:68617-64-1，SPDP acid，3-(2-吡啶二硫代)丙酸的合成方法 |
116 |
zyl |
2024-12-19 |
| 73510 |
1,4,7,10-四(羧甲基)-1,4,7,10-四氮杂环十二烷单酰胺偶联葡萄糖 |
82 |
h |
2024-12-19 |
| 73511 |
PEG-P(Asp-Gd-DOTA)Gd‐DOTA偶联聚乙二醇改性聚天冬氨酸 |
86 |
h |
2024-12-19 |
| 73512 |
cas:70539-42-3，EGS Crosslinker，乙二醇-双(琥珀酸N-羟基琥珀酰亚胺酯)的结构式 |
134 |
zyl |
2024-12-19 |
| 73513 |
CXCR4导向的五肽[(68)Ga]喷替沙福(环(-D-Tyr-N-Me-D-Orn(AMB-DOTA)-L-Arg-L-2-Nal-Gly-)) |
114 |
h |
2024-12-19 |
| 73514 |
α-hexadecyl-DOTA α-十六烷基-DOTA |
82 |
h |
2024-12-19 |
| 73515 |
Methyltetrazine-SS-NHS 甲基四唑-双硫键-活性酯的合成方法 |
72 |
zyl |
2024-12-19 |
| 73516 |
DOTA-AgRP-6E |
109 |
h |
2024-12-19 |
| 73517 |
DOTA-morab-003 DOTA偶联单克隆抗体MORAb-003 |
72 |
h |
2024-12-19 |
| 73518 |
DOTA-Bz-folate DOTA-Bz-叶酸 |
88 |
h |
2024-12-19 |
| 73519 |
cas:55750-53-3，6-Maleimidocaproic acid，6-马来酰亚氨基己酸 |
100 |
zyl |
2024-12-19 |
| 73520 |
cas: Fmoc-PEG3-Val-Cit，ADC定制 |
78 |
wyh |
2024-12-19 |
| 73521 |
钆(III)DOTA-DSPE脂质体 |
76 |
h |
2024-12-19 |
| 73522 |
CAS: 870487-08-4，Boc-Val-Cit，叔丁氧羰基-缬氨酰-L-瓜氨酸 |
69 |
WYQ |
2024-12-19 |
| 73523 |
DOTA-Phe-D-Trp-Lys-Thr-OMe DOTA偶联生长抑素四肽类似物 |
99 |
h |
2024-12-19 |
| 73524 |
CAS: 35665-38-4，Fmoc-Gly-Gly-OH，Fmoc-甘氨酰-甘氨酸 |
102 |
WYQ |
2024-12-19 |
| 73525 |
cas:117235-10-6，3-Mercaptopropanyl-N-hydroxysuccinimide ester的结构式 |
102 |
zyl |
2024-12-19 |
| 73526 |
DOTA-PEG(4)-BBN(7-14)-AuNP DOTA-神经介素n功能化NHS活化的PEG-金纳米颗粒 |
70 |
h |
2024-12-19 |
| 73527 |
cas:2226472-28-0，DBCO-PEG4-Val-Cit-PAB-PNP，ADC定制 |
64 |
wyh |
2024-12-19 |
| 73528 |
CAS: 863971-53-3，Fmoc-Val-Cit-PAB-PNP |
81 |
WYQ |
2024-12-19 |
| 73529 |
tris-苄基-DOTA tris-benzyl-DOTA |
101 |
h |
2024-12-19 |
| 73530 |
DOTA-DN(PTX)-BN DOTA-铃蟾肽功能化聚酰胺胺(PAMAM)树状大分子(DN)负载紫杉醇 |
88 |
h |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询